| A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. | A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence.
Brückmann NH, Bennedsen SN, Duijf PHG, Terp MG, Thomassen M, Larsen M, Pedersen CB, Kruse T, Alcaraz N, Ditzel HJ, Gjerstorff MF., Free PMC Article | 08/29/2020 |
| co-expression of and interplay between Rab3IP and SSX2 during gastric cancer progression | Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells.
Ren H, Xu Z, Guo W, Deng Z, Yu X. | 01/19/2019 |
| We conclude from these findings that SSX2 expression in prostate cancer is not a driver of the epithelial to mesenchymal transition (EMT), but is involved in processes associated with EMT including loss of focal adhesion that may be related to tumor cell dissemination | SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.
Bloom JE, McNeel DG., Free PMC Article | 02/3/2018 |
| Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18-SSX2 tumors. Re-analysis of human SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 expression in SS18-SSX1 tumors. | The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.
Jones KB, Barrott JJ, Xie M, Haldar M, Jin H, Zhu JF, Monument MJ, Mosbruger TL, Langer EM, Randall RL, Wilson RK, Cairns BR, Ding L, Capecchi MR., Free PMC Article | 09/2/2017 |
| results reveal two important phenotypes of ectopic SSX2 expression that may drive/support tumorigenesis: First, immediate induction of genomic instability, and second, long-term support of tumor cell growth. | Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.
Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt S, Mollenhauer J, Kristensen SB, Andersen RS, Relster MM, Ditzel HJ, Gjerstorff MF., Free PMC Article | 09/26/2015 |
| The tumor-specific pattern of expression of SSX2. | Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA., Free PMC Article | 06/6/2015 |
| primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation | Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D., Free PMC Article | 02/28/2015 |
| SS18-SSX-induced Wnt/beta-catenin signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression. | SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W. | 12/20/2014 |
| SSX2, SSX3, and SSX4 are expressed in the lung tissue of only 3.5% early-stage non-small cell lung cancer patients. | SSX2-4 expression in early-stage non-small cell lung cancer.
Greve KB, Pøhl M, Olsen KE, Nielsen O, Ditzel HJ, Gjerstorff MF. | 12/6/2014 |
| These results suggest that the characteristic speckle localization pattern of SS18-SSX is strongly involved in the tumorigenesis through the SSX moiety of the SS18-SSX fusion protein. | Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y, Ito S, Kunisada T, Morimoto Y, Kanzaki H, Yoshida A, Shimizu K, Ozaki T, Ouchida M., Free PMC Article | 06/14/2014 |
| the initial events that likely occur when SYT-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation | Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.
Garcia CB, Shaffer CM, Alfaro MP, Smith AL, Sun J, Zhao Z, Young PP, VanSaun MN, Eid JE., Free PMC Article | 11/3/2012 |
| The regulation of estrogen receptor alpha signaling by target proteins of SSX2 may explain the metastatic potential of breast cancer cells. | Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling.
Chen L, Zhou WB, Zhao Y, Liu XA, Ding Q, Zha XM, Wang S. | 08/4/2012 |
| demonstrate differentially expressed genes for the 2 major gene fusion variants in SS, chromosome 18 synovial sarcoma (SS18)/SSX1 and SS18/SSX2, and thereby suggest that these result in different downstream effects | Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma.
Fernebro J, Francis P, Edén P, Borg A, Panagopoulos I, Mertens F, Vallon-Christersson J, Akerman M, Rydholm A, Bauer HC, Mandahl N, Nilbert M. | 01/21/2010 |
| We report the identification of an HLA-DR3-restricted epitope mapping to the 37-51 region of SSX-2. | Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.
Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D. | 01/21/2010 |
| Two kinds of cancer-testis antigen, SSX-2 and SSX-5 showed high-specific and high-frequent expression in hepatocellular carcinoma tissues, but neither of them could be detected in adjacent non-HCC tissues. | Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.
Wu LQ, Lu Y, Wang XF, Lv ZH, Zhang B, Yang JY. | 01/21/2010 |
| existence of fusion with SYT in synovial sarcoma | Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.
Yang K, Lui WO, Xie Y, Zhang A, Skytting B, Mandahl N, Larsson C, Larsson O. | 01/21/2010 |
| The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RABIN3, and a novel nuclear protein, SSX2IP. | The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP.
de Bruijn DR, dos Santos NR, Kater-Baats E, Thijssen J, van den Berk L, Stap J, Balemans M, Schepens M, Merkx G, van Kessel AG. | 01/21/2010 |
| RT-PCR detection of SSX2 in paraffin-embedded tissue allowed for molecular diagnosis of synovial sarcoma. | Molecular diagnosis of synovial sarcoma: RT-PCR detection of SYT-SSX1/2 fusion transcripts in paraffin-embedded tissue.
Tvrdík D, Povýsil C, Svatosová J, Dundr P. | 01/21/2010 |